NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mazor Robotics Ltd. (NASDAQ: MZOR ), Kinross Gold Corporation (NYSE: KGC ), Mimecast Limited (NASDAQ: MIME ), DBV Technologies S.A. (NASDAQ: DBVT ), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ), and Adverum Biotechnologies, Inc. (NASDAQ: ADVM ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
MZOR DOWNLOAD: http://Fundamental-Markets.com/register/?so=MZOR KGC DOWNLOAD: http://Fundamental-Markets.com/register/?so=KGC MIME DOWNLOAD: http://Fundamental-Markets.com/register/?so=MIME DBVT DOWNLOAD: http://Fundamental-Markets.com/register/?so=DBVT ADMS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADMS ADVM DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADVM
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Mazor Robotics Ltd. (NASDAQ: MZOR ), Kinross Gold Corporation (NYSE: KGC ), Mimecast Limited (NASDAQ: MIME ), DBV Technologies S.A. (NASDAQ: DBVT ), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ), and Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed August 16th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
MAZOR ROBOTICS LTD. (MZOR) REPORT OVERVIEW
Mazor Robotics' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Mazor Robotics reported revenue of $13.24MM vs $15.46MM (down 14.34%) and basic earnings per share -$0.14 vs -$0.16. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Mazor Robotics reported revenue of $64.95MM vs $36.38MM (up 78.53%) and basic earnings per share -$0.50 vs -$0.84. Mazor Robotics is expected to report earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.15. The estimated EPS forecast for the next fiscal year is $0.10 and is expected to report on February 13th, 2019.
To read the full Mazor Robotics Ltd. (MZOR) report, download it here: http://Fundamental-Markets.com/register/?so=MZOR
-----------------------------------------
KINROSS GOLD CORPORATION (KGC) REPORT OVERVIEW
Kinross Gold's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Kinross Gold reported revenue of $775.00MM vs $868.60MM (down 10.78%) and basic earnings per share $0.00 vs $0.03. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Kinross Gold reported revenue of $3,303.00MM vs $3,472.00MM (down 4.87%) and basic earnings per share $0.36 vs -$0.08. Kinross Gold is expected to report earnings on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.07. The estimated EPS forecast for the next fiscal year is $0.19 and is expected to report on February 13th, 2019.
To read the full Kinross Gold Corporation (KGC) report, download it here: http://Fundamental-Markets.com/register/?so=KGC
-----------------------------------------
MIMECAST LIMITED (MIME) REPORT OVERVIEW
Mimecast's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Mimecast reported revenue of $78.40MM vs $58.16MM (up 34.81%) and basic earnings per share -$0.06 vs -$0.03. For the twelve months ended March 31st, 2018 vs March 31st, 2017, Mimecast reported revenue of $261.90MM vs $186.56MM (up 40.38%) and basic earnings per share -$0.22 vs -$0.10. Mimecast is expected to report earnings on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.02. The estimated EPS forecast for the next fiscal year is $0.08 and is expected to report on May 13th, 2019.
To read the full Mimecast Limited (MIME) report, download it here: http://Fundamental-Markets.com/register/?so=MIME
-----------------------------------------
DBV TECHNOLOGIES S.A. (DBVT) REPORT OVERVIEW
DBV Technologies S.A's Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, DBV Technologies S.A reported revenue of $13.46MM vs $10.05MM (up 33.91%) and basic earnings per share -$3.38 vs -$2.59.
To read the full DBV Technologies S.A. (DBVT) report, download it here: http://Fundamental-Markets.com/register/?so=DBVT
-----------------------------------------
ADAMAS PHARMACEUTICALS, INC. (ADMS) REPORT OVERVIEW
Adamas Pharmaceuticals' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Adamas Pharmaceuticals reported revenue of $7.57MM vs $0.00MM and basic earnings per share -$1.26 vs -$0.93. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Adamas Pharmaceuticals reported revenue of $0.57MM vs $0.57MM (down 0.17%) and basic earnings per share -$3.97 vs -$2.77. Adamas Pharmaceuticals is expected to report earnings on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$1.04. The estimated EPS forecast for the next fiscal year is -$3.76 and is expected to report on February 28th, 2019.
To read the full Adamas Pharmaceuticals, Inc. (ADMS) report, download it here: http://Fundamental-Markets.com/register/?so=ADMS
-----------------------------------------
ADVERUM BIOTECHNOLOGIES, INC. (ADVM) REPORT OVERVIEW
Adverum Biotechnologies' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Adverum Biotechnologies reported revenue of $0.49MM vs $0.46MM (up 6.48%) and basic earnings per share -$0.30 vs -$0.27. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Adverum Biotechnologies reported revenue of $1.85MM vs $1.46MM (up 27.08%) and basic earnings per share -$1.29 vs -$3.14. Adverum Biotechnologies is expected to report earnings on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.32. The estimated EPS forecast for the next fiscal year is -$1.30 and is expected to report on March 5th, 2019.
To read the full Adverum Biotechnologies, Inc. (ADVM) report, download it here: http://Fundamental-Markets.com/register/?so=ADVM
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
